SUISSA S, ERNST P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001;107:937-944.
NEVILLE RG, PEARSON MG, RICHARDS N, PATIENCE J, SONDHI S, WAGSTAFF B et al. A cost analysis on the pattern of asthma prescribing in the UK. Eur Respir J 1999;14:605-609.
GREENING AP, IND PW, NORTHfiELD M, SHAW G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-224.
PAUWELS RA, LOFDAHL CG, POSTMA DS, TATTERSfiELD AE, O'Byrne P, BARNES PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-1411.
Global Strategy for Asthma Management and Prevention. NIH publication no. 02-3659. Updated from NHLBI/ WHO Workshop Report: Global Strategy for Asthma Management and Prevention issued January, 1995, 2002.
SPECTOR SL, SMITH LJ, GLASS M. Effects of 6 weeks of therapy with oral doses of ICI 204, 219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-623.
VAQUERIZO MJ, CASAN P, CASTILLO J, PERPINA M, SANCHIS J, SOBRADILLO V et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58: 204-210.
PRESTA LG, LAHR SJ, SHIELDS RL, PORTER JP, GORMAN CM, FENDLY BM et al. Humanization of an antibody directed against IgE. J Immunol 1993;151:2623-2632.
CORNE J, DJUKANOVIC R, THOMAS L, WARNER J, BOTTA L, GRANDORDY B et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997;99:879-887.
FAHY JV, FLEMING HE, WONG HH, LIU JT, SU JQ, REIMANN J et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155: 1828-1834.
MILGROM H, FICK RB Jr, SU JQ, REIMANN JD, BUSH RK, WATROUS ML et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhu-MAb-E25 Study Group. N Engl J Med 1999;341:1966-1973.
BUSSE W, CORREN J, LANIER BQ, MCALARY M, FOWLER-TAYLOR A, CIOPPA GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
SOLER M, MATZ J, TOWNLEY R, BUHL R, O'BRIEN J, FOX H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18: 254-261.
BUHL R, HANF G, SOLER M, BENSCH G, WOLFE J, EVERHARD F et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088-1094.
FINN A, GROSS G, van BAVEL J, LEE T, WINDOM H, EVERHARD F et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111:278-284.
ADELROTH E, RAK S, HAAHTELA T, AASAND G, ROSENHALL L, ZETTERSTROM O et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106: 253-259.
CHERVINSKY P, CASALE T, TOWNLEY R, TRIPATHY I, HEDGECOCK S, FOWLER-TAYLOR A et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:160-167.
BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N, ARIA WORKSHOP GROUP, WHO. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-334.
VIGNOLA AM, HUMBERT M, BOUSQUET J, BOULET L-P, HEDGECOCK S, BLOGG M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59: 709-717.
AYRES JG, HIGGINS B, CHILVERS ER, AYRE G, BLOGG M, FOX H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59:701-708.
BRIGHTLING CE, BRADDING P, SYMON FA, HOLGATE ST, WARDLAW AJ, PAVORD ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699-1705.
MACGLASHAN DW JR, BOCHNER BS, ADELMAN DC, JARDIEU PM, TOGIAS A, MCKENZIE-WHITE J et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-1445.
LEYNAERT B, BOUSQUET J, NEUKIRCH C, LIARD R, NEUKIRCH F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999;104:301-304.
BURROWS B, MARTINEZ FD, HALONEN M, BARBEE RA, CLINE MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-277.
HUMBERT M, GRANT JA, TABORDA-BARATA L, DURHAM SR, PfiSTER R, MENZ G et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996;153:1931-1937.
ISHIZAKA K, ISHIZAKA T, HORNBROOK MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966;97:75-85.
JOHANSSON SG, BENNICH H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967;13:381-394.
